Bristol-Myers Squibb (Strategic Investments)

Bristol-Myers Squibb (Strategic Investments) BMS makes strategic investments directly from its balance sheet rather than through a dedicated CVC fund. Typical deal sizes run $10-50M, with fewer than 2 new investments per year. The approach is selective and strategically driven. The major venture investment was $180M in Owkin, a French AI company developing technology for clinical trial design, in 2022. BMS also anchored Life Science Partners' record €600M European VC fund. On the M&A side, the s